Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study

被引：2

作者：

Shi, Minke ^{[1
]}

Ma, Jing ^{[2
]}

Feng, Meilin ^{[2
]}

Liang, Lei ^{[3
]}

Chen, Hongyuan ^{[3
]}

Wang, Tao ^{[1
]}

Xie, Zhenghua ^{[3
]}

机构：

[1] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Thorac Surg, Affiliated Hosp,Med Sch, Nanjing, Peoples R China

[2] 3D Med Inc, Dept Data Syst, Shanghai, Peoples R China

[3] 3D Med Inc, Dept Res & Dev, Shanghai, Peoples R China

来源：

CANCER GENETICS | 2021年 / 256卷

关键词：

MET alterations; MET exon 14 skipping analog; NGS; Oncogenic driver; MET; MUTATIONS; NONSENSE; INHIBITORS; MECHANISM; MISSENSE;

D O I：

10.1016/j.cancergen.2021.04.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MET exon 14 skipping (METex14) is a validated oncogenic driver in lung cancer and MET tyrosine kinase inhibitors are now available as effective clinical treatments. The majority of known METex14 alterations are typical donor/acceptor splicing or ubiquitination site mutations. Herein, two new METex14 variants were detected in two patients with lung adenocarcinoma by targeted next generation sequencing (NGS). Reverse transcription (RT)-based analysis confirmed that these mutations led to MET exon 14 skipping. Our analysis provided evidence for possible targeted therapy options for patients carrying these MET mutations or similar METex14 analogs. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

引用

页码：62 / 67

页数：6

共 50 条

[41] MET alterations in advanced non-small cell lung cancer
Chagas, Gabriel Cavalcante Lima
Rangel, Amanda Ribeiro
El Osta, Badi
CURRENT PROBLEMS IN CANCER, 2024, 49
[42] Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer
Qiu, Tian
Li, Weihua
Zhang, Tongtong
Xing, Puyuan
Huang, Wenting
Wang, Bingning
Chu, Lixia
Guo, Lei
Liu, Xiuyun
Li, Yan
Ying, Jianming
Li, Junling
CLINICAL LUNG CANCER, 2018, 19 (04) : E391 - E398
[43] Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
Watari, Naokazu
Yamaguchi, Kakuhiro
Terada, Hiroaki
Hamai, Kosuke
Masuda, Ken
Nishimura, Yoshifumi
Sakamoto, Shinjiro
Masuda, Takeshi
Horimasu, Yasushi
Miyamoto, Shintaro
Nakashima, Taku
Iwamoto, Hiroshi
Shoda, Hiroyasu
Ishikawa, Nobuhisa
Fujitaka, Kazunori
Miyazaki, Kozue
Miyata, Yoshihiro
Hamada, Hironobu
Awai, Kazuo
Hattori, Noboru
BMC PULMONARY MEDICINE, 2022, 22 (01)
[44] Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis
Huy Gia Vuong
An Thi Nhat Ho
Altibi, Ahmed M. A.
Nakazawa, Tadao
Katoh, Ryohei
Kondo, Tetsuo
LUNG CANCER, 2018, 123 : 76 - 82
[45] Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer
Suzawa, Ken
Offin, Michael
Lu, Daniel
Kurzatkowski, Christopher
Vojnic, Morana
Smith, Roger S.
Sabari, Joshua K.
Tai, Huichun
Mattar, Marissa
Khodos, Inna
de Stanchina, Elisa
Rudin, Charles M.
Kris, Mark G.
Arcila, Maria E.
Lockwood, William W.
Drilon, Alexander
Ladanyi, Marc
Somwar, Romel
CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1248 - 1260
[46] Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Wolf, Juergen
Seto, Takashi
Han, Ji-Youn
Reguart, Noemi
Garon, Edward B.
Groen, Harry J. M.
Tan, Daniel S. W.
Hida, Toyoaki
de Jonge, Maja
Orlov, Sergey V.
Smit, Egbert F.
Souquet, Pierre-Jean
Vansteenkiste, Johan
Hochmair, Maximilian
Felip, Enriqueta
Nishio, Makoto
Thomas, Michael
Ohashi, Kadoaki
Toyozawa, Ryo
Overbeck, Tobias R.
de Marinis, Filippo
Kim, Tae-Min
Laack, Eckart
Robeva, Anna
Le Mouhaer, Sylvie
Waldron-Lynch, Maeve
Sankaran, Banu
Balbin, O. Alejandro
Cui, Xiaoming
Giovannini, Monica
Akimov, Mikhail
Heist, Rebecca S.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (10) : 944 - 957
[47] Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
Drusbosky, Leylah M.
Dawar, Richa
Rodriguez, Estelamari
Ikpeazu, Chukwuemeka, V
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[48] Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer
Bahcall, Magda
Awad, Mark M.
Sholl, Lynette M.
Wilson, Frederick H.
Xu, Man
Wang, Stephen
Palakurthi, Sangeetha
Choi, Jihyun
Ivanova, Elena V.
Leonardi, Giulia C.
Ulrich, Bryan C.
Paweletz, Cloud P.
Kirschmeier, Paul T.
Watanabe, Masayuki
Baba, Hideo
Nishino, Mizuki
Nagy, Rebecca J.
Lanman, Richard B.
Capelletti, Marzia
Chambers, Emily S.
Redig, Amanda J.
VanderLaan, Paul A.
Costa, Daniel B.
Imamura, Yu
Janne, Pasi A.
CLINICAL CANCER RESEARCH, 2018, 24 (23) : 5963 - 5976
[49] The Landscape of MET Alterations in Chinese Non-Small Cell Lung Cancer Patients
Zheng, M.
Jun, P.
Wang, S.
Li, M.
Mao, N.
Liu, Y.
Cheng, T.
Lan, H.
Zhao, J.
Wang, W.
Hu, J.
Yao, M.
Wang, K.
Qu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S567 - S567
[50] MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
Lung, Jrhau
Hung, Ming-Szu
Lin, Yu-Ching
Lee, Kam-Fai
Jiang, Yuan Yuan
Huang, Shao-Lan
Fang, Yu-Hung
Lu, Ming-Shian
Lin, Chin-Kuo
Yang, Tsung-Ming
Lin, Paul Yann
Hsieh, Meng-Jer
Tsai, Ying Huang
PLOS ONE, 2019, 14 (08):

← 1 2 3 4 5 →